CO2022015170A2 - Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas - Google Patents

Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas

Info

Publication number
CO2022015170A2
CO2022015170A2 CONC2022/0015170A CO2022015170A CO2022015170A2 CO 2022015170 A2 CO2022015170 A2 CO 2022015170A2 CO 2022015170 A CO2022015170 A CO 2022015170A CO 2022015170 A2 CO2022015170 A2 CO 2022015170A2
Authority
CO
Colombia
Prior art keywords
cas12i2
polypeptide variants
compositions
complexes
polypeptide variant
Prior art date
Application number
CONC2022/0015170A
Other languages
English (en)
Spanish (es)
Inventor
Shaorong Chong
Brendan Jay Hilbert
Quinton Norman Wessells
Noah Michael Jakimo
Roy Ziblat
Jason Michael Carte
Tia Marie Ditommaso
Jeffrey Raymond Haswell
Anthony James Garrity
Colin Alexander Mcgaw
David A Scott
Derek Michael Cerchione
Original Assignee
Arbor Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Biotechnologies Inc filed Critical Arbor Biotechnologies Inc
Publication of CO2022015170A2 publication Critical patent/CO2022015170A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CONC2022/0015170A 2020-03-31 2022-10-25 Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas CO2022015170A2 (es)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202063003090P 2020-03-31 2020-03-31
US202063002999P 2020-03-31 2020-03-31
US202063003064P 2020-03-31 2020-03-31
US202063012007P 2020-04-17 2020-04-17
US202063026277P 2020-05-18 2020-05-18
US202063026562P 2020-05-18 2020-05-18
US202063026606P 2020-05-18 2020-05-18
US202063026523P 2020-05-18 2020-05-18
US202063063879P 2020-08-10 2020-08-10
US202063063831P 2020-08-10 2020-08-10
US202063063859P 2020-08-10 2020-08-10
US202063063819P 2020-08-10 2020-08-10
US202063085862P 2020-09-30 2020-09-30
US202063085792P 2020-09-30 2020-09-30
US202063085752P 2020-09-30 2020-09-30
US202063085895P 2020-09-30 2020-09-30
US202163147850P 2021-02-10 2021-02-10
US202163147968P 2021-02-10 2021-02-10
PCT/US2021/025257 WO2021202800A1 (en) 2020-03-31 2021-03-31 Compositions comprising a cas12i2 variant polypeptide and uses thereof

Publications (1)

Publication Number Publication Date
CO2022015170A2 true CO2022015170A2 (es) 2022-11-08

Family

ID=75640000

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015170A CO2022015170A2 (es) 2020-03-31 2022-10-25 Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas

Country Status (12)

Country Link
US (1) US20230332119A1 (enExample)
EP (1) EP4127154A1 (enExample)
JP (1) JP2023520504A (enExample)
KR (1) KR20230009379A (enExample)
CN (2) CN121380024A (enExample)
AU (1) AU2021249119A1 (enExample)
BR (1) BR112022019713A2 (enExample)
CA (1) CA3177749A1 (enExample)
CO (1) CO2022015170A2 (enExample)
IL (1) IL296791A (enExample)
MX (1) MX2022012189A (enExample)
WO (1) WO2021202800A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US20230193243A1 (en) * 2020-05-29 2023-06-22 Arbor Biotechnologies, Inc. Compositions comprising a cas12i2 polypeptide and uses thereof
EP4237557A1 (en) * 2020-10-30 2023-09-06 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting pdcd1 and uses thereof
EP4347818A2 (en) * 2021-06-01 2024-04-10 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
IL308803A (en) 2021-06-04 2024-01-01 Arbor Biotechnologies Inc Gene editing systems comprising guide RNA targeting hydroxy acid oxidase 1 (HAO1) and uses thereof
US20230034581A1 (en) * 2021-06-04 2023-02-02 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting lactate dehydrogenase a (ldha) and uses thereof
WO2022256619A2 (en) 2021-06-04 2022-12-08 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting transthyretin (ttr) and uses thereof
WO2023018856A1 (en) 2021-08-11 2023-02-16 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting polypyrimidine tract binding protein 1 (ptbp1) and uses thereof
US20230203539A1 (en) 2021-08-11 2023-06-29 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting stathmin 2 (stmn2) and uses thereof
WO2023034475A1 (en) 2021-09-01 2023-03-09 Arbor Biotechnologies, Inc. Cells modified by a cas12i polypeptide
EP4399293A4 (en) * 2021-09-10 2025-10-15 Arbor Biotechnologies Inc COMPOSITIONS COMPRISING A CAS12I POLYPEPTIDE AND USES THEREOF
CA3237337A1 (en) * 2021-11-02 2023-05-11 Huidagene Therapeutics (Singapore) Pte. Ltd. Novel crispr-cas12i systems and uses thereof
TW202334421A (zh) * 2021-11-05 2023-09-01 美商阿伯生物技術公司 包含靶向ciita之rna引導之組合物及其用途
WO2023122433A1 (en) 2021-12-22 2023-06-29 Arbor Biotechnologies, Inc. Gene editing systems targeting hydroxyacid oxidase 1 (hao1) and lactate dehydrogenase a (ldha)
CN118749029A (zh) * 2022-01-24 2024-10-08 辉大(上海)生物科技有限公司 新型CRISPR-Cas12i系统及其用途
CN118995668A (zh) * 2022-04-25 2024-11-22 辉大基因治疗(新加坡)私人有限公司 新型CRISPR-Cas12i系统及其用途
EP4627083A1 (en) 2022-11-30 2025-10-08 Arbor Biotechnologies, Inc. Reverse transcriptase-mediated genetic editing of transthyretin (ttr) and uses thereof
KR20250151430A (ko) 2023-02-15 2025-10-21 아버 바이오테크놀로지스, 인크. 스타스민 2(stmn2) 전사체에서 비정상적인 스플라이싱을 억제하는 유전자 편집 방법
WO2025096594A2 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof
CN117431235A (zh) * 2023-11-06 2024-01-23 微光基因(苏州)有限公司 CRISPR-Cas系统及其应用
WO2025147604A1 (en) 2024-01-05 2025-07-10 Arbor Biotechnologies, Inc. Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1
WO2025171210A1 (en) 2024-02-09 2025-08-14 Arbor Biotechnologies, Inc. Compositions and methods for gene editing via homology-mediated end joining
WO2026015829A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Small reverse transcriptases and gene editing systems comprising such
WO2026015832A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Reverse transcriptases and gene editing systems comprising such
CN120424908B (zh) * 2025-07-10 2025-09-12 南京农业大学 一种基于LAMP与CRISPR/Cas的检测方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CN105492611A (zh) * 2013-06-17 2016-04-13 布罗德研究所有限公司 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
WO2019178427A1 (en) * 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
JP7693552B2 (ja) * 2019-02-13 2025-06-17 ビーム セラピューティクス インク. アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法
WO2024178144A1 (en) * 2023-02-22 2024-08-29 Prime Medicine, Inc. Methods and compositions for editing nucleotide sequences

Also Published As

Publication number Publication date
WO2021202800A1 (en) 2021-10-07
CN121380024A (zh) 2026-01-23
IL296791A (en) 2022-11-01
JP2023520504A (ja) 2023-05-17
BR112022019713A2 (pt) 2022-12-20
MX2022012189A (es) 2023-01-05
CN115698278A (zh) 2023-02-03
KR20230009379A (ko) 2023-01-17
EP4127154A1 (en) 2023-02-08
CN115698278B (zh) 2025-10-17
CA3177749A1 (en) 2021-10-07
US20230332119A1 (en) 2023-10-19
AU2021249119A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
CO2022015170A2 (es) Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas
ECSP19021312A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CO2018010715A2 (es) Compuestos bicíclicos
CL2019001293A1 (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía.
MX2023010508A (es) Composiciones que comprenden un polipéptido variante y usos de las mismas.
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
MX386520B (es) Polimorfos de sepiapterina y sales de los mismos.
MX2019011778A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
UY39390A (es) Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo
MX2019013293A (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de animo.
CO2020012963A2 (es) Composición farmacéutica y método de fabricación
UY40418A (es) Métodos y composiciones para mejorar características de rendimiento en plantas
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
CO2023011697A2 (es) Composiciones que comprenden un polipéptido cas12i4 variante y usos de las mismas
CO2024012454A2 (es) Composiciones que comprenden aticaprant
MX2025009863A (es) Formulaciones solidas y formas polimorficas de inhibidores de indolina de kif18a
ECSP19091293A (es) Nuevas formulaciones orales de belinostat
PY2107343A (es) Supresión de la respuesta de escape a la sombra en plantas
MX2023007643A (es) Ensamblaje in vitro de cápsides de anellovirus que encierran arn.